Objective response by inverse probability weighting–adjusted analysis for all patients and according to chemotherapy regimen
| All | Docetaxel | Docetaxel+Ramucirumab | S-1 | Pemetrexed | ||||||
| CAP | Control | CAP | Control | CAP | Control | CAP | Control | CAP | Control | |
| No. of patients | 228 | 1130 | 101 | 734 | 61 | 84 | 46 | 151 | 12 | 122 |
| ORR (%) | 18.9 | 11.0 | 17.6 | 11.4 | 20.9 | 18.3 | 6.0 | 6.0 | 53.6 | 9.8 |
| ORR ratio (95% CI), p value* | 1.71 (1.19 to 2.46), 0.004 | 1.55 (0.95 to 2.51), 0.08 | 1.14 (0.58 to 2.26), 0.70 | 1.01 (0.26 to 3.90), 0.987 | 5.47 (2.32 to 12.91), <0.001 | |||||
*The relative risk (95% CI) is shown for the ORR ratio. The control cohort was the reference cohort for calculation of relative risk, with a relative risk >1 thus favoring the CAP cohort.
CAP, chemotherapy after PD-1 inhibitor treatment; ORR, objective response rate.